Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. (CVSI) operates at the intersection of scientific innovation and natural wellness, developing hemp-derived supplements and plant-based nutrition solutions. This page serves as the definitive source for official company announcements, research breakthroughs, and operational developments.
Investors and industry stakeholders will find curated updates spanning regulatory milestones, product launches, and peer-reviewed studies validating CVSI's formulations. The archive includes earnings reports, manufacturing expansions, and clinical trial outcomes supporting their +PlusCBD and Cultured Foods brands.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards and scientific accuracy. Users can efficiently track the company's progress in obtaining self-affirmed GRAS statuses, scaling global distribution networks, and advancing pet wellness innovations.
Bookmark this resource for real-time access to CV Sciences' advancements in cannabinoid research, nutraceutical safety protocols, and strategic partnerships within the consumer health sector. Regularly updated to reflect the company's evolving role in science-driven wellness solutions.
CV Sciences, Inc. announced the launch of +PlusCBD™ Reserve Collection Extra Gummies on April 3, 2023. These gummies offer a potent blend of 25mg CBD and 5mg THC, aimed at enhancing wellness through improved sleep, recovery, and relaxation. The new formulation features organic ingredients, is gluten-free, soy-free, and vegan. With a focus on customizable wellness, the company positions these Extra Gummies as a higher THC alternative in their product range. CV Sciences emphasizes their commitment to high-quality manufacturing practices, third-party lab testing, and science-backed products, making them a top-selling brand in the hemp extract market.
CV Sciences reported revenue of $16.2 million for fiscal 2022, down from $20.0 million in 2021, reflecting a 19% decline primarily due to reduced retail sales and supply chain challenges. In Q4 2022, revenue rose 3% sequentially to $3.9 million, but was down 22% year-over-year. Gross margin decreased to 34.2% for the year compared to 43.0% in 2021. Operating expenses were cut by 54% to $12.4 million, resulting in a reduced operating loss of $6.8 million. The company generated positive cash flow of $0.2 million in Q4 2022, the best since Q2 2019. Initiatives for future growth include new product launches and cost efficiency improvements.
CV Sciences, Inc. (OTCQB:CVSI) announced it will release its financial results for the year and fourth quarter ended December 31, 2022, on March 29, 2023, before market open. A conference call with investors is scheduled for 7:00 a.m. PT the same day. The call can be accessed via telephone or through a webcast available on the Company's Investor Relations page. CV Sciences specializes in hemp extracts and other natural wellness products, with its PlusCBD™ brand being a top seller in the market, adhering to Good Manufacturing Practices (GMP). Investors can expect insights into the Company's financial performance and strategic direction during the call.
FAQ
What is the current stock price of Cv Sciences (CVSI)?
What is the market cap of Cv Sciences (CVSI)?
